Table 1.
Variation in Gag Cleavage Sites in Subtype A Viruses
| Gag Cleavage Sites | |||||||
|---|---|---|---|---|---|---|---|
| Patient number | Trial arm | Time point | MA/CA 128–137 VSQNY/PIVQN | CA/p2 359–368 KARVL/AEAMS | P2/NC 373–382 TXXIM/MQRGN | NC/p1 428–437 ERQAN/FLGKI | p1/p6 444–453 RPGNF/LQSRP |
| 1 | CT | Pre-PI | -----/----- | -----/----- | HTH--/----- | EK----/----- | -----/P---- |
| Failure | -----/----- | --K--/----- | HTN--/----- | -----/----- | -----/P---- | ||
| 2 | bPImono | Pre-PI | -----/----- | -----/----- | QTS--/--K-M | -----/----- | -----/P---- |
| Failure | -----/----- | -----/----- | HTN--/--K-M | -----/----- | -----/P---- | ||
| 3 | bPImono | Pre-PI | -----/----- | ---I-/----- | QPN--/----- | -----/----- | -----/P-N-L |
| Failure | -----/----- | --KI-/----- | Q-N--/----- | -----/----- | -----/P-N-L | ||
| 4 | bPImono | Pre-PI | -----/----- | -----/----- | QTN--/--RK-- | -----/----- | -----/P---PL |
| Failure | -----/----- | -----/----- | QTN--/--K-- | -----/----- | -----/P---- | ||
| 5 | bPImono | Pre-PI | -----/----- | -----/----- | NHAT---/----- | -----/----- | -----/P---- |
| Failure | -----/----- | -----/----- | H-N--/----- | -----/----- | -----/P---- | ||
| 6 | bPImono | Pre-PI | -----/----- | -----/----- | NTK--/----- | -----/----- | -----/P---L |
| Failure | -----/----- | -----/----- | NTK--/----- | -----/----- | -----/P---L | ||
| 7 | bPImono | Pre-PI | +----/-V--- | -----/----- | NTK--/----- | -----/----- | -----/P---L |
| Failure | -----/-V--- | -----/----- | QPN--/----- | -----/----- | -----/P--RKL | ||
| 8 | bPImono | Pre-PI | -----/----- | -----/----K | PTN--/I---- | -----/----- | -----/P---- |
| Failure | -----/----- | -----/----K | PTN--/I---- | -----/----- | -----/P---L | ||
| 9 | bPImono | Pre-PI | -----/----- | -----/----- | QTNV-/----- | -----/----- | -----/P---- |
| Failure | -----/----- | -----/----- | QTSV-/----- | -----/---RK- | -----/P---- | ||
| 10 | bPImono | Pre-PI | -----/----- | -----/----- | NTN--/----- | -----/---RL | -----/P---- |
| Failure | -----/----- | -----/----- | NTN--/----- | -----/---RL | -----/P---- | ||
| 11 | CT | Pre-PI | -----/----- | -----/----- | PTN--/----- | -----/----- | -----/P---- |
| Failure | -----/----- | -----/----- | PTN--/----- | -----/----- | -----/P---- | ||
The sequence at each of the Gag cleavage sites is shown for the 11 patients infected with subtype A viruses, both at pre-PI therapy and at treatment failure time points. Sequences were compared with the HIV-1 group M consensus sequence9 using HXB2 numbering. Where no consensus residue was derived an X is present. Deletions are shown by + and mixed residues by superscript letters. Clinical trial arm is shown: boosted PI monotherapy (bPImono) and continuation on combination therapy (CT).